We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+2.89%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.86B
AUM Growth
+$29.2M
Cap. Flow
+$147M
Cap. Flow %
5.13%
Top 10 Hldgs %
48.59%
Holding
107
New
12
Increased
2
Reduced
2
Closed
19

Top Buys

Rank Stock Value
1
TYRA icon
Tyra Biosciences
TYRA
+$121M
2
TNGX icon
Tango Therapeutics
TNGX
+$82.4M
3
BPMC
Blueprint Medicines
BPMC
+$39.6M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$37.4M
5
NUVL
Nuvalent
NUVL
+$35.1M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$63.2M
2
AMRN
Amarin Corp
AMRN
+$26.3M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$24M
4
AGEN
Agenus
AGEN
+$22M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$20.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.15%
2 Financials 0.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TPTX
26
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$34.9M 1.22%
+525,000
New +$37.4M
GOSS icon
27
Gossamer Bio
GOSS
$82.9M
$31M 1.08%
2,462,358
-100,000
-4% -$921K
DAWN
28
DELISTED
Day One Biopharmaceuticals
DAWN
$28.2M 0.99%
1,189,943
– –
RNAM
29
DELISTED
Avidity Biosciences
RNAM
$27.6M 0.96%
1,121,327
– –
MRNS
30
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$27.3M 0.95%
2,400,000
– –
NUVL
31
DELISTED
Nuvalent
NUVL
$27.3M 0.95%
+1,210,192
New +$35.1M
IOVA icon
32
Iovance Biotherapeutics
IOVA
$1.82B
$27.1M 0.95%
+1,100,000
New +$25.9M
BMEA icon
33
Biomea Fusion
BMEA
$84.6M
$25M 0.87%
2,088,405
– –
CGEM icon
34
Cullinan Oncology
CGEM
$1.01B
$24.2M 0.85%
1,074,082
– –
ALGS icon
35
Aligos Therapeutics
ALGS
$26.2M
$23.7M 0.83%
61,042
– –
GHRS icon
36
GH Research
GHRS
$1.93B
$22.4M 0.78%
1,013,399
– –
CNTA
37
DELISTED
Centessa Pharmaceuticals
CNTA
$22.3M 0.78%
1,334,227
+430,000
+48% +$8.9M
FOLD
38
DELISTED
Amicus Therapeutics
FOLD
$22.2M 0.78%
2,325,000
– –
PRTA icon
39
Prothena Corp
PRTA
$425M
$21.4M 0.75%
+300,000
New +$18.6M
BCAB icon
40
BioAtla
BCAB
$5.46M
$20.2M 0.71%
13,727
– –
KURA icon
41
Kura Oncology
KURA
$800M
$19.7M 0.69%
1,050,289
– –
CABA icon
42
Cabaletta Bio
CABA
$437M
$19.5M 0.68%
1,603,361
– –
PNT
43
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$19.2M 0.67%
2,500,000
– –
PASG icon
44
Passage Bio
PASG
$14.4M
$19.2M 0.67%
96,416
– –
AKRO
45
DELISTED
Akero Therapeutics
AKRO
$18.6M 0.65%
831,495
– –
BLU
46
DELISTED
BELLUS Health Inc.
BLU
$18.3M 0.64%
2,975,000
– –
RAIN
47
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$17.6M 0.61%
1,175,000
– –
BDTX icon
48
Black Diamond Therapeutics
BDTX
$96.8M
$17M 0.6%
2,014,858
– –
CDAK
49
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$16.8M 0.59%
1,030,065
– –
SPRY icon
50
ARS Pharmaceuticals
SPRY
$509M
$16.7M 0.58%
1,675,377
– –
1
2
3 4 5

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Boxer Capital held 107 positions worth $2.86B, up 1% from $2.83B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Boxer Capital deployed $147M of net new capital in Q3 2021, opening 12 new positions and adding to 2 existing holdings. Its largest new stake was Tyra Biosciences: 6,323,359 shares worth $111M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Solid Biosciences, an estimated $1.42M trimmed.

  • Boxer Capital's largest Q3 2021 buy was Tyra Biosciences: 6,323,359 shares worth $111M.
  • Boxer Capital added most to Kinnate Biopharma Inc. Common Stock in Q3 2021, an estimated $17M increase.
  • Boxer Capital's biggest Q3 2021 reduction was Solid Biosciences, cutting an estimated $1.42M.
  • Boxer Capital fully exited Seagen Inc. Common Stock in Q3 2021, selling an estimated $63.2M.
  • Boxer Capital's ten largest holdings make up 49% of its $2.86B portfolio in Q3 2021.
  • Boxer Capital opened 12 new positions and closed 19 in Q3 2021.
  • Boxer Capital's portfolio value rose 1% quarter-over-quarter to $2.86B.

Based on Boxer Capital's 13F filing for Q3 2021, filed 15 Nov 2021.